CDK15 Antibody (YA8353)

CDK15 (cyclin-dependent kinase 15), also known as PFTAIRE2, belongs to the cyclin-dependent kinase family of serine/threonine protein kinases that regulate cell-cycle progression and phosphorylation-dependent signaling networks.^[1][2] Mechanistically, CDK15 is predicted to possess cyclin-dependent protein kinase activity and to participate in regulation of cell-cycle phase transitions, with localization in both the cytoplasm and nucleus.^[2] These characteristics place CDK15 within the broader CDK signaling framework that coordinates proliferation, transcriptional control, and cellular homeostasis.^[1] In disease-related studies, elevated CDK15 expression has been reported in breast cancer tissues and is associated with advanced TNM stage, lymph-node metastasis, increased tumor diameter, and shorter overall survival, supporting its relevance as a candidate biomarker in tumor biology.^[3] Compared with better-characterized CDK isoforms that have established functions and clinically validated inhibitors, CDK15 remains relatively understudied, and its molecular regulation and substrate spectrum require further experimental definition.^[1][2] For experimental applications, CDK15 has attracted interest as a kinase target because recombinant CDK15-cyclin complexes can be biochemically characterized and evaluated using kinase-activity assays and inhibitor panels, providing a platform for mechanistic studies and early-stage drug-discovery research.^[4]